Monoamine oxidase and tobacco dependence

A Lewis, JH Miller, RA Lea - Neurotoxicology, 2007 - Elsevier
Tobacco smoking is a leading cause of preventable death around the world, and there are
major public health and research efforts in many countries aimed at reducing its usage …

Current and emerging pharmacotherapies for cessation of tobacco smoking

N Gómez‐Coronado, AJ Walker… - … : The Journal of …, 2018 - Wiley Online Library
Tobacco use disorder is a chronic illness. With its high comorbidity rate, it is a major cause of
years of life lost or years lived with disability; however, it is also considered the most …

Smoking-induced ventral striatum dopamine release

AL Brody, RE Olmstead, ED London… - American Journal of …, 2004 - Am Psychiatric Assoc
OBJECTIVE: Substantial evidence from animal models demonstrates that dopamine release
in the ventral striatum underlies the reinforcing properties of nicotine. The authors used …

Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area

SR Laviolette, D van der Kooy - Molecular psychiatry, 2003 - nature.com
Nicotine produces rewarding and aversive motivational effects in humans and other animal
species. Here, we report that the mammalian ventral tegmental area (VTA) represents a …

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

M Andreoli, M Tessari, M Pilla, E Valerio… - …, 2003 - nature.com
Drugs of abuse, including, nicotine have been shown to enhance brain reward functions in
the mesocortico-limbic dopamine (DA) system in general, and the nucleus accumbens in …

The role of dopamine in human addiction: from reward to motivated attention

IHA Franken, J Booij, W van den Brink - European journal of pharmacology, 2005 - Elsevier
There is general consensus among preclinical researchers that dopamine plays an
important role in the development and persistence of addiction. However, the precise role of …

Advances in pharmacotherapy for tobacco dependence

J Foulds, M Burke, M Steinberg… - Expert opinion on …, 2004 - Taylor & Francis
The discovery that bupropion is an effective treatment for tobacco dependence has triggered
a rapid increase in development of potential new non-nicotine pharmacotherapies, including …

Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system

MA Patriquin, IE Bauer, JC Soares… - Psychiatric …, 2015 - journals.lww.com
Substance use disorders have significant personal, familial, and societal consequences.
Despite the serious consequences of substance use, only a few therapies are effective in …

New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline?

E Beard, L Shahab, DM Cummings, S Michie, R West - CNS drugs, 2016 - Springer
A wide range of support is available to help smokers to quit and to aid attempts at harm
reduction, including three first-line smoking cessation medications: nicotine replacement …

The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions

AC Pak, CR Ashby Jr, CA Heidbreder… - International Journal …, 2006 - academic.oup.com
Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the
nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement …